regulatory status comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved in the US, EU and Australia | Sale and import restricted; no licensed product |
| Typical test matrices | Urine, serum, seized powder | Urinary detection window is short |
| Primary identification method | LC-MS/MS against a reference standard | High-resolution mass used for confirmation |
| Data sources in the literature | Small trials, case reports, pharmacovigilance | No registrational trial dataset exists |
| Common marketing names | Melanotan 2, MT-II, MT-2 | Label content may not match declared peptide |
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
Regulatory treatment varies by jurisdiction and has changed over time. In several countries the peptide is handled as an unapproved prescription medicine, and import or sale for human use is restricted, while elsewhere it falls under poisons or controlled-substance schedules. Enforcement activity against online vendors has been reported in Australia, New Zealand, the United Kingdom and the United States. Scholarly writing discusses melanotan-2 chiefly as an experimental tool and as a case study in unregulated peptide supply, and its precise legal position in any given country should be checked against current national schedules.
Lyophilised melanotan-2 is comparatively robust when kept dry, cold and dark, and a desiccated powder stored at minus twenty degrees Celsius or below is generally expected to retain its chemical integrity for extended periods. In solution the peptide is far less stable, with degradation proceeding through oxidation of tryptophan and histidine residues, hydrolysis adjacent to the lactam bridge, and aggregation at higher concentrations. Repeated freeze-thaw cycling accelerates loss of the parent peak. Working aliquots are therefore prepared once, held cold, and used without letting the stock return to ambient temperature.
On March 5, 1946, Winston Churchill, while at Westminster College in Fulton, Missouri, gave his speech "The Sinews of Peace", declaring that an "iron curtain" had descended across Europe. From the standpoint of the Soviets, the speech was an incitement for the West to begin a war with the USSR, as it called for an Anglo-American alliance against the Soviets.
== Death and race continuation == On March 27, 2012, True failed to return after heading out for a run in the Gila Wilderness, part of the Gila National Forest in southwestern New Mexico. He departed from the Wilderness Lodge in Gila, saying he was going for a 12-mile (19 km) run. A subsequent mountain rescue effort involved three aircraft and at least nine search and rescue teams in off-road vehicles and on horseback, looking across 200,000 acres (81,000 ha) of high desert. Searchers included ultra-runners such as Scott Jurek, Kyle Skaggs, Timothy Olson, and many athletes and friends who had participated in the 51 mile Copper Canyon Ultra Marathon. On March 31, True was found dead with his legs dangling in a stream. The local sheriff said there were "no obvious signs of trauma", although True had scrapes and abrasions on his hands, arms, and knees, suggesting a fall. His remains were removed by horseback. Because of difficult terrain and remote location, the recovery was not completed until April 1. An autopsy was inconclusive with respect to the actual cause of death, revealing, however, that True was suffering from idiopathic cardiomyopathy, which had caused the left ventricle of his heart to become enlarged.
== ANA subtypes == ANAs are found in many disorders, as well as some healthy individuals. These disorders include: systemic lupus erythematosus (SLE), rheumatoid arthritis, Sjögren syndrome, scleroderma, polymyositis, dermatomyositis, primary biliary cirrhosis, drug induced lupus, autoimmune hepatitis, multiple sclerosis, discoid lupus, thyroid disease, antiphospholipid syndrome, juvenile idiopathic arthritis, psoriatic arthritis, juvenile dermatomyositis, idiopathic thrombocytopaenic purpura, infection and cancer. These antibodies can be subdivided according to their specificity, and each subset has different propensities for specific disorders.
Sources: en.wikipedia.org
=== Homoleptic complexes (only amino acid ligands) === Mixing simple metal salts with solutions of amino acids near neutral or elevated pH often affords bis- or tris complexes. For metal ions that prefer octahedral coordination, these complexes often adopt the stoichiometry M(aa)3 (aa = amino carboxylate, such as glycinate, H2NCH2CO2−). Complexes of the 3:1 stoichiometry have the formula [M(O2CC(R)HNH2)3]z. Such complexes adopt octahedral coordination geometry. These complexes can exist in facial and meridional isomers, both of which are chiral. The stereochemical possibilities increase when the amino acid ligands are not homochiral. Both the violet meridional and red-pink facial isomers of tris(glycinato)cobalt(III) have been characterized With L-alanine, L-leucine, and other amino acids, one obtains four stereoisomers. With cysteine, the amino acid binds through N and thiolate. Complexes with the 2:1 stoichiometry are illustrated by copper(II) glycinate [Cu(O2CC(R)HNH2)2], which akso exists as a pentacoordinate monohydrate. When the metal is square planar, these complexes can exist as cis and trans isomers. The stereochemical possibilities increase when the amino acid ligands are not homochiral. Homoleptic complexes are also known where the amino carboxylate is tridentate amino acids. One such complex is Ni(κ3-histidinate)2.
Another important property of elements is their electronegativity. Atoms can form covalent bonds to each other by sharing electrons in pairs, creating an overlap of valence orbitals. The degree to which each atom attracts the shared electron pair depends on the atom's electronegativity – the tendency of an atom towards gaining or losing electrons. The more electronegative atom will tend to attract the electron pair more, and the less electronegative (or more electropositive) one will attract it less. In extreme cases, the electron can be thought of as having been passed completely from the more electropositive atom to the more electronegative one, though this is a simplification. The bond then binds two ions, one positive (having given up the electron) and one negative (having accepted it), and is termed an ionic bond. Electronegativity depends on how strongly the nucleus can attract an electron pair, and so it exhibits a similar variation to the other properties already discussed: electronegativity tends to fall going up to down, and rise going left to right. The alkali and alkaline earth metals are among the most electropositive elements, while the chalcogens, halogens, and noble gases are among the most electronegative ones. Electronegativity is generally measured on the Pauling scale, on which the most electronegative reactive atom (fluorine) is given electronegativity 4.0, and the least electronegative atom (caesium) is given electronegativity 0.79.
A text known as The Ritual of Embalming does describe some of the practical logistics of embalming; however, there are only two known copies and each is incomplete. With regards to mummification shown in images, there are apparently also very few. The tomb of Tjay, designated TT23, is one of only two known which show the wrapping of a mummy (Riggs 2014). Another text that describes the processes being used in the latter periods is Herodotus' Histories. Written in Book 2 of the Histories is one of the most detailed descriptions of the Egyptian mummification process, including the mention of using natron in order to dehydrate corpses for preservation. However, these descriptions are short and fairly vague, leaving scholars to infer the majority of the techniques that were used by studying mummies that have been unearthed. By utilizing current advancements in technology, scientists have been able to uncover a plethora of new information about the techniques used in mummification. A series of CT scans performed on a 2,400-year-old mummy in 2008 revealed a tool that was left inside the cranial cavity of the skull. The tool was a rod, made of an organic material, that was used to break apart the brain to allow it to drain out of the nose. This discovery helped to dispel the claim within Herodotus' works that the rod had been a hook made of iron. Earlier experimentation in 1994 by researchers Bob Brier and Ronald Wade supported these findings.
=== Sleep, tobacco, and alcohol === Inadequate/irregular sleep and untreated obstructive sleep apnoea increase metabolic and CV risk. Smoking increases insulin resistance and CV risk; cessation reduces adverse outcomes. High alcohol intake raises BP, TGs, and hepatic steatosis; moderation is advised.
Sources: en.wikipedia.org
Ecologists have formulated and tested hypotheses regarding the nature of ecological patterns associated with food chain length, such as length increasing with ecosystem volume, limited by the reduction of energy at each successive level, or reflecting habitat type. Food chain length is important because the amount of energy transferred decreases as trophic level increases; generally only ten percent of the total energy at one trophic level is passed to the next, as the remainder is used in the metabolic process. There are usually no more than five tropic levels in a food chain. Humans are able to receive more energy by going back a level in the chain and consuming the food before, for example getting more energy per pound from consuming a salad than an animal which ate lettuce.
=== Vitamin D synthesis === PTH upregulates the activity of 1-α-hydroxylase enzyme, which converts 25-hydroxycholecalciferol, the major circulating form of inactive vitamin D, into 1,25-dihydroxycholecalciferol, the active form of vitamin D, in the kidney.
PABA is an intermediate in the synthesis of folate by bacteria, plants, and fungi. Many bacteria, including those found in the human intestinal tract such as E. coli, generate PABA from chorismate by the combined action of the enzymes 4-amino-4-deoxychorismate synthase and 4-amino-4-deoxychorismate lyase. Plants produce PABA in their chloroplasts, and store it as a glucose ester (pABA-Glc) in their tissues. The malarial protozoan Plasmodium only make PABA when necessary, preferring to get it from the surroundings if able to. Some bacteria, including a few found in the human microbiome, are unable to make PABA for themselves but can use PABA to make folate. A few are very efficient at the PABA-to-folate conversion despite not making their own PABA. Sulfonamide drugs are structurally similar to PABA, and their antibacterial activity is due to their ability to interfere with the conversion of PABA to folate by the enzyme dihydropteroate synthetase. Thus, bacterial growth is limited through folate deficiency.
In this case, the three substrates of this enzyme are cyanidin, reduced nicotinamide adenine dinucleotide phosphate (NADPH), and a proton. It converts them to (–)-epicatechin and oxidised NADP+. The enzyme from the legume Medicago truncatula can use nicotinamide adenine dinucleotide as an alternative cofactor. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-CH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is flavan-3-ol:NAD(P)+ oxidoreductase. Other names in common use include AtANR, and MtANR. This enzyme participates in flavonoid biosynthesis.
The region has been strongly Protestant since the time of the Protestant Reformation. It is proportionally the most Protestant of the sixteen modern states. In 2018, members of the Protestant Church in Germany made up 44.6% of the population, while members of the Catholic Church comprised 6.1%. 49.3% either adhere to other religions or disclaim any practising religious identity.
Sources: en.wikipedia.org
Regulatory treatment varies by country. In the United States, the European Union and Australia it is an unapproved drug and its sale is restricted, while some other jurisdictions list it as prescription-only or controlled. The applicable rules depend on the country of import.
Reversed-phase LC-MS/MS is the usual approach for both identification and quantitation. High-resolution mass spectrometry and peptide mapping serve as confirmatory methods. Immunoassays are rarely used alone because of cross-reactivity.
Published testing of seized and purchased samples frequently reports discrepancies between declared and measured peptide content. Counter-ion content and residual solvents add further variation. Independent analysis is the only way to confirm composition.
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.